
    
      This is a multicentre, parallel group, two arm, unblinded, randomized clinical trial to
      compare two management strategies for patients with ischemic heart disease and recurrent ICD
      therapy despite at least one antiarrhythmic drug. The primary endpoint will be a composite of
      appropriate ICD shocks or death.
    
  